ArticleThoracic cancer2016

Long-lasting response to third-line crizotinib treatment in a patient with non-small cell lung cancer with brain metastases and poor performance status.

De-Lan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.